These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 29113464

  • 1. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
    Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH.
    Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
    [Abstract] [Full Text] [Related]

  • 2. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J, Blunt E, Gupta D, Edison P.
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [Abstract] [Full Text] [Related]

  • 3. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.
    Verma A, Goyal A.
    Eur J Pharmacol; 2024 Nov 05; 982():176936. PubMed ID: 39182542
    [Abstract] [Full Text] [Related]

  • 4. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO, Glotfelty EJ, Li Y, Greig NH.
    Pharmacol Res; 2022 Dec 05; 186():106550. PubMed ID: 36372278
    [Abstract] [Full Text] [Related]

  • 5. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH.
    Curr Med Res Opin; 2016 Dec 05; 32(1):61-76. PubMed ID: 26439329
    [Abstract] [Full Text] [Related]

  • 6. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.
    Chen SD, Chuang YC, Lin TK, Yang JL.
    Eur J Pharmacol; 2023 Jan 05; 938():175439. PubMed ID: 36470445
    [Abstract] [Full Text] [Related]

  • 7. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.
    Salcedo I, Tweedie D, Li Y, Greig NH.
    Br J Pharmacol; 2012 Jul 05; 166(5):1586-99. PubMed ID: 22519295
    [Abstract] [Full Text] [Related]

  • 8. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
    Athauda D, Foltynie T.
    Drug Discov Today; 2016 May 05; 21(5):802-18. PubMed ID: 26851597
    [Abstract] [Full Text] [Related]

  • 9. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
    Ferrari F, Moretti A, Villa RF.
    Pharmacol Ther; 2022 Nov 05; 239():108277. PubMed ID: 36064147
    [Abstract] [Full Text] [Related]

  • 10. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
    Athauda D, Foltynie T.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):260-270. PubMed ID: 28927992
    [Abstract] [Full Text] [Related]

  • 11. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH, Jeon SJ, Cho KS, Moon E, Sapkota A, Jun HS, Ryu JH, Choi JW.
    Mol Neurobiol; 2018 Apr 01; 55(4):3007-3020. PubMed ID: 28456941
    [Abstract] [Full Text] [Related]

  • 12. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.
    BMJ; 2012 Jan 10; 344():d7771. PubMed ID: 22236411
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR, Hurren KM.
    Ann Pharmacother; 2011 Jul 10; 45(7-8):850-60. PubMed ID: 21730278
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M, Harris K, Brackett A.
    Ann Pharmacother; 2012 Jan 10; 46(1):68-78. PubMed ID: 22232377
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic potential of spinal GLP-1 receptor signaling.
    Zhang D, Lv G.
    Peptides; 2018 Mar 10; 101():89-94. PubMed ID: 29329976
    [Abstract] [Full Text] [Related]

  • 16. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
    Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A, Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, Greig NH.
    Proc Natl Acad Sci U S A; 2009 Jan 27; 106(4):1285-90. PubMed ID: 19164583
    [Abstract] [Full Text] [Related]

  • 17. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P.
    Rev Neurol; 2014 Dec 01; 59(11):517-24. PubMed ID: 25418147
    [Abstract] [Full Text] [Related]

  • 18. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Serné EH, van Raalte DH.
    Arterioscler Thromb Vasc Biol; 2016 Oct 01; 36(10):2125-32. PubMed ID: 27562916
    [Abstract] [Full Text] [Related]

  • 19. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec 01; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 20. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, Hölscher C.
    J Parkinsons Dis; 2020 Dec 01; 10(2):523-542. PubMed ID: 31958096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.